twenty-nine evaluable patients with acute nonlymphoblastic leukemia ( anll ) , either in relapse or resistant to initial induction therapy ( ara c , daunorubicin + etoposide ) , received the ata regime consisting of 100 mg/m2 per day ara c by i.v . infusion for 4-5 days , 100 mg/m2 per day thioguanine orally for 4-5 days , and 100 mg/m2 per day amsacrine i.v . for 2-5 days .
C0023467
acute nonlymphoblastic leukemia
C0011015
daunorubicin